683269-95-6

Basic information

• Product Name: Carbamic acid, [trans-4-[[(methylsulfonyl)oxy]methyl]cyclohexyl]-, 1,1-dimethylethyl ester
• CAS NO: 683269-95-6
• Molecular Formula: C13H25NO5S
• Molecular Weight: 307.411
• Mol File: 683269-95-6.mol
• Article Data: 16

Chemical Properties

• CAS DataBase Reference: Carbamic acid, [trans-4-[[(methylsulfonyl)oxy]methyl]cyclohexyl]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [trans-4-[[(methylsulfonyl)oxy]methyl]cyclohexyl]-, 1,1-dimethylethyl ester(683269-95-6)
• EPA Substance Registry System: Carbamic acid, [trans-4-[[(methylsulfonyl)oxy]methyl]cyclohexyl]-, 1,1-dimethylethyl ester(683269-95-6)

Safety Data

• Hazardous Substances Data: 683269-95-6(Hazardous Substances Data)

Upstream product

• 53292-90-3 trans-4-(tert-butoxycarbonylamino)cyclohexanoic acid 
• 239074-29-4 trans (4-hydroxymethyl-cyclohexyl)-carbamic acid tert-butyl ester 
• 7143-01-3 Methanesulfonic anhydride 
• 24424-99-5 di-tert-butyl dicarbonate 
• 27960-59-4 trans-4-aminocyclohexanecarboxylic acid hydrochloric acid 
• 62456-15-9 methyl trans-4-amino-cyclohexanecarboxylate 
• 146307-51-9 methyl (1R,4R)-4-((tert-butoxycarbonyl)amino)cyclohexane-1-carboxylate 
• 15177-67-0 trans-4-(methoxycarbonyl)cyclohexanecarboxylic acid 
• 124-63-0 methanesulfonyl chloride 

Downstream Products

• 956352-36-6 N-[(trans)-4-(azidomethyl)cyclohexyl]carbamic acid tert-butyl ester 
• 506427-91-4 trans N-tert-butoxycarbonyl-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]ethyl}-cyclohexylamine 
• 791778-53-5 trans-4-(2-(4-(2,3-dichlorophenyl)piperazin-1-yl)ethyl)cyclohexane-1-amine 
• 215790-29-7 trans-2-(1-(4-(N-tert-butoxycarbonyl)amino)cyclohexyl)acetaldehyde 
• 1313279-47-8 trans-(4-cyanomethyl-cyclohexyl)-carbamic acid tert-butyl ester 

Relevant articles and documents

SSAO INHIBITORS AND USE THEREOF

Provided are a compound of formula (I') or (I), a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of SSAO, a pharmaceutical composition comprising a compound of formula (I') or (I), and a method of treating or preventing a disease in which SSAO plays a role.

Generation of highly potent DYRK1A-dependent inducers of human β-Cell replication via Multi-Dimensional compound optimization

Small molecule stimulation of β-cell regeneration has emerged as a promising therapeutic strategy for diabetes. Although chemical inhibition of dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) is sufficient to enhance β-cell replicat

FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST

The present invention relates to fused cyclic urea derivatives which have antagonistic activities against CRHR1 and/or CRHR2, and which are useful in the treatment or prevention of disorders and diseases in which CRHR1 and/or CRHR2 is involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CRHR1 and/or CRHR2 is involved.